Theravance Biopharma (TBPH) Competitors $13.65 +0.26 (+1.96%) As of 03:10 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TBPH vs. GMTX, RXRX, CPRX, KNSA, OGN, ALVO, CNTA, IBRX, TARS, and OCULShould you be buying Theravance Biopharma stock or one of its competitors? The main competitors of Theravance Biopharma include Gemini Therapeutics (GMTX), Recursion Pharmaceuticals (RXRX), Catalyst Pharmaceuticals (CPRX), Kiniksa Pharmaceuticals International (KNSA), Organon & Co. (OGN), Alvotech (ALVO), Centessa Pharmaceuticals (CNTA), ImmunityBio (IBRX), Tarsus Pharmaceuticals (TARS), and Ocular Therapeutix (OCUL). These companies are all part of the "pharmaceutical products" industry. Theravance Biopharma vs. Its Competitors Gemini Therapeutics Recursion Pharmaceuticals Catalyst Pharmaceuticals Kiniksa Pharmaceuticals International Organon & Co. Alvotech Centessa Pharmaceuticals ImmunityBio Tarsus Pharmaceuticals Ocular Therapeutix Theravance Biopharma (NASDAQ:TBPH) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment. Is TBPH or GMTX more profitable? Theravance Biopharma has a net margin of 16.88% compared to Gemini Therapeutics' net margin of 0.00%. Theravance Biopharma's return on equity of 6.93% beat Gemini Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Theravance Biopharma16.88% 6.93% 3.52% Gemini Therapeutics N/A -38.78%-35.88% Which has stronger earnings and valuation, TBPH or GMTX? Theravance Biopharma has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTheravance Biopharma$64.38M10.68-$56.42M$0.2456.89Gemini TherapeuticsN/AN/A-$71.87M-$1.00-58.72 Which has more volatility and risk, TBPH or GMTX? Theravance Biopharma has a beta of 0.01, meaning that its share price is 99% less volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the S&P 500. Do analysts rate TBPH or GMTX? Theravance Biopharma currently has a consensus target price of $21.33, suggesting a potential upside of 56.25%. Given Theravance Biopharma's stronger consensus rating and higher probable upside, research analysts plainly believe Theravance Biopharma is more favorable than Gemini Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Theravance Biopharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor TBPH or GMTX? In the previous week, Theravance Biopharma had 7 more articles in the media than Gemini Therapeutics. MarketBeat recorded 7 mentions for Theravance Biopharma and 0 mentions for Gemini Therapeutics. Theravance Biopharma's average media sentiment score of 0.31 beat Gemini Therapeutics' score of 0.00 indicating that Theravance Biopharma is being referred to more favorably in the media. Company Overall Sentiment Theravance Biopharma Neutral Gemini Therapeutics Neutral Do insiders and institutionals hold more shares of TBPH or GMTX? 99.1% of Theravance Biopharma shares are held by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are held by institutional investors. 6.9% of Theravance Biopharma shares are held by insiders. Comparatively, 12.9% of Gemini Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryTheravance Biopharma beats Gemini Therapeutics on 15 of the 16 factors compared between the two stocks. Get Theravance Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TBPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TBPH vs. The Competition Export to ExcelMetricTheravance BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$688.62M$2.49B$5.75B$9.56BDividend YieldN/A1.66%4.53%4.07%P/E Ratio56.9822.4530.4425.14Price / Sales10.68547.14391.6287.40Price / CashN/A173.7937.0358.50Price / Book3.065.259.006.20Net Income-$56.42M$31.83M$3.26B$265.38M7 Day Performance5.51%0.75%1.00%-1.13%1 Month Performance20.29%3.65%4.23%-0.70%1 Year Performance69.81%9.77%28.45%18.99% Theravance Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TBPHTheravance Biopharma2.196 of 5 stars$13.65+2.0%$21.33+56.3%+62.9%$688.62M$64.38M56.98110GMTXGemini TherapeuticsN/A$59.86-1.4%N/A+16.5%$2.59BN/A-59.8630RXRXRecursion Pharmaceuticals2.5768 of 5 stars$5.52-4.3%$7.00+26.8%-33.4%$2.51B$58.84M-3.10400News CoverageInsider TradeCPRXCatalyst Pharmaceuticals4.9111 of 5 stars$20.23flat$33.20+64.1%-1.7%$2.48B$491.73M12.2680Positive NewsAnalyst DowngradeKNSAKiniksa Pharmaceuticals International2.4271 of 5 stars$33.72+1.0%$41.17+22.1%+26.1%$2.47B$423.24M843.21220Insider TradeOGNOrganon & Co.4.7141 of 5 stars$9.27-1.8%$18.00+94.2%-54.9%$2.45B$6.40B3.454,000Positive NewsALVOAlvotech2.6006 of 5 stars$9.00+12.2%$14.00+55.6%-35.0%$2.42B$491.98M39.131,032Trending NewsAnalyst DowngradeShort Interest ↓High Trading VolumeCNTACentessa Pharmaceuticals2.1772 of 5 stars$17.59-2.5%$28.10+59.7%+43.8%$2.42B$6.85M-9.83200Analyst RevisionIBRXImmunityBio2.2937 of 5 stars$2.43-4.7%$10.75+342.4%-43.1%$2.41B$14.74M-5.06590TARSTarsus Pharmaceuticals1.8382 of 5 stars$54.61+0.7%$66.67+22.1%+111.2%$2.29B$182.95M-23.4450OCULOcular Therapeutix4.0529 of 5 stars$12.31-2.5%$17.20+39.7%+35.3%$2.20B$63.72M-9.62230 Related Companies and Tools Related Companies GMTX Alternatives RXRX Alternatives CPRX Alternatives KNSA Alternatives OGN Alternatives ALVO Alternatives CNTA Alternatives IBRX Alternatives TARS Alternatives OCUL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TBPH) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theravance Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theravance Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access